Clinical Trial Update: A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating different doses of BI 1358894 in borderline personality disorder has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Personality Disorder

Drugs mentioned

• BI-1358894

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Borderline Personality Disorder | Phase 2 | Status: COMPLETED | Results posted: 2024-01-30